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AbstrACt
Objective The best strategy in patients with acute ST-
segment elevation myocardial infarction (STEMI) with 
multivessel coronary artery disease (CAD) regarding 
completeness of revascularisation of the non-culprit 
lesion(s) is still unclear. To establish which strategy should 
be followed, survival rates over a longer period should 
be evaluated. The aim of this study was to investigate 
whether complete revascularisation, compared with 
incomplete revascularisation, is associated with reduced 
short-term and long-term all-cause mortality in patients 
with first STEMI and multivessel CAD.
Methods This retrospective study consisted of 518 
patients with first STEMI with multivessel CAD. Complete 
revascularisation (45%) was defined as the treatment of 
any significant coronary artery stenosis (≥70% luminal 
narrowing) during primary or staged percutaneous 
coronary intervention prior to discharge. The primary end 
point was all-cause mortality.
Results Incomplete revascularisation was not 
independently associated with 30-day all-cause mortality 
in patients with acute first STEMI and multivessel CAD 
(OR 1.98; 95% CI 0.62to6.37; p=0.25). During a median 
long-term follow-up of 6.7 years, patients with STEMI 
with multivessel CAD and incomplete revascularisation 
showed higher mortality rates compared with patients 
who received complete revascularisation (24% vs 12%, 
p<0.001), and these differences remained after excluding 
the first 30 days. However, in multivariate analysis, 
incomplete revascularisation was not independently 
associated with increased all-cause mortality during long-
term follow-up in the group of patients with STEMI who 
survived the first 30 days post-STEMI (HR 1.53 95% CI 
0.89-2.61, p=0.12).
Conclusion In patients with acute first STEMI and 
multivessel CAD, incomplete revascularisation compared 
with complete revascularisation was not independently 
associated with increased short-term and long-term all-
cause mortality.
IntroduCtIon
Primary percutaneous coronary interven-
tion (PCI) of the culprit vessel in patients 
with ST-segment elevation myocardial infarc-
tion (STEMI) is a standard clinical practice.1 
However, in patients with STEMI and 
multivessel coronary artery disease (CAD), 
the best revascularisation strategy (complete 
vs incomplete revascularisation) remains 
debated. While primary PCI of the infarct-re-
lated artery (IRA) should be performed 
systematically, immediate revascularisation of 
the non-culprit vessel(s) is/are only recom-
mended in patients with cardiogenic shock 
Interventional cardiology
Key messAges
What is already known about this subject?
 ► Whether incomplete revascularisation in patients 
with first ST-segment elevation myocardial 
infarction (STEMI) and multivessel coronary artery 
disease (CAD) is associated with worse outcome 
as compared with complete revascularisation 
remains debated. Current evidence is conflicting; 
smaller randomised trials demonstrated superior 
outcome after complete revascularisation, 
whereas large registries demonstrated no benefit 
of complete over incomplete revascularisation.
What does this study add?
 ► To establish which strategy should be followed, 
survival rates over a longer period may be of 
importance. In this retrospective, observational 
study, incomplete revascularisation (corrected 
for baseline characteristics) was not associated 
with increased short-term and long-term all-
cause mortality in patients with first STEMI with 
multivessel CAD, as compared with complete 
revascularisation.
How might this impact on clinical practice?
 ► The current retrospective, observational study 
(with longer term follow-up) supports findings 
of previous registries (with shorter follow-up), 
suggesting that complete revascularisation has no 
benefit on all-cause mortality as compared with 
incomplete revascularisation in patients with first 
STEMI with multivessel CAD.
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or persisting large areas of ischaemia.2 Recent landmark 
randomised trials such as the CvLPRIT (Complete versus 
Lesion-only Primary PCI trial), DANAMI-3 -PRIMULTI 
(The Third Danish Study of Optimal Acute treatment 
of Patients with STEMI:Primary PCI in Multivessel 
disease)  and the PRAMI (Preventive Angioplasty in Acute 
Myocardial Infarction) trials demonstrated reduced risk 
of adverse cardiovascular events in patients undergoing 
immediate complete revascularisation compared with 
patients with incomplete revascularisation.3–5 In contrast, 
large observational studies did not show differences 
in adverse cardiovascular event rates between the two 
revascularisation strategies.6–8 Furthermore, the effect of 
complete versus incomplete revascularisation on clinical 
outcomes has not been evaluated at long-term follow-up 
(>5 years).9 10
Therefore, the aim of the current retrospective, obser-
vational study was to investigate whether incomplete 
revascularisation, compared with complete revascularisa-
tion, is associated with increased short-term and long-term 
all-cause mortality in patients with acute first STEMI and 
multivessel CAD.
methods
Patients
The analysis concerns a retrospective analysis of patients 
who presented with a first acute STEMI and multivessel 
CAD at the Leiden University Medical Center (The Neth-
erlands) between 2004 and 2008. The inclusion criteria 
were: (1) diagnosis of first acute STEMI that was defined as 
typical chest pain complaints <12 hours, elevated cardiac 
enzyme levels and significant ST-segment elevation or left 
bundle branch block on the ECG; (2) multivessel CAD 
on emergency coronary angiography (CAG) and (3) no 
history of CAD as defined by previous myocardial infarc-
tion, PCI or coronary artery bypass graft. All patients were 
treated according to the MISSION! protocol as described 
earlier, which was based on the most recent American 
College of Cardiology/American Heart Association and 
European Society of Cardiology guidelines for patients 
with acute myocardial infarction at that moment.11 The 
interventional cardiologist determined whether imme-
diate or staged revascularisation of the non-culprit 
vessel(s) occurred. Patients with (1) emergent or staged 
revascularisation with coronary artery bypass graft surgery 
before discharge and (2) incomplete or uninterpretable 
CAG images were excluded. The primary end point was 
all-cause mortality. Mortality data were obtained from 
hospital’s files review or municipal civil registries. Demo-
graphic, clinical and angiographic data were prospectively 
entered in the departmental Cardiology Information 
System (EPD-Vision; Leiden University Medical Center, 
The Netherlands) and analysed retrospectively. The Insti-
tutional Review Board of the Leiden University Medical 
Centre approved the retrospective, observational study 
and waived the need for written informed consent for 
retrospective analysis of clinically acquired data.
Primary percutaneous coronary intervention and 
angiographic data analysis
CAG data were acquired from standardised angiographic 
projections according to the guidelines of the Amer-
ican College of Cardiology/American Heart Association 
and were stored digitally.12 CAG data were reviewed 
retrospectively by two experienced observers. During 
image analysis the following information was reported: 
(in)complete revascularisation, coronary vessel domi-
nance, culprit vessel, severity of CAD and the results of 
primary PCI. IRA was determined by the evaluation of 
acute electrocardiographic changes on the ECG at admis-
sion.13 Complete revascularisation was defined as PCI of 
any significant coronary artery stenosis (≥70% luminal 
narrowing) of any vessel during the primary or staged 
PCI prior to discharge.
statistical analysis
Normally distributed variables were expressed as mean±SD 
and non-normally distributed variables as median and IQR. 
Categorical variables were presented as frequencies and 
percentages. Differences in baseline characteristics between 
patients with complete revascularisation and patients with 
incomplete revascularisation were evaluated with the inde-
pendent samples t-test, the Mann-Whitney U test or the χ2 
test when appropriate. Survival analyses were performed 
using Kaplan-Meier analysis. Cumulative event rates for the 
end point of all-cause mortality were compared between 
patients with complete revascularisation and patients with 
incomplete revascularisation, using the log-rank test. The 
influence of differences in baseline characteristics on 
30-day mortality post-STEMI was assessed by performing 
univariate and multivariate logistic regression analysis. To 
avoid any overfitting of the model, only a selection of vari-
ables with significant p values (<0.05) at univariate analysis 
were entered in the multivariate model: age, three-vessel 
CAD, culprit vessel left main, Killip class ≥2 and incomplete 
revascularisation. The results of the multivariate analysis 
were reported as adjusted OR with 95% CI. The indepen-
dent associates of all-cause mortality at long-term follow-up 
were investigated using univariate and multivariate Cox 
regression analysis for those patients who survived the first 
30 days. Only variables with significant p-values (<0.05) at 
univariate analysis were included in the multivariate model: 
age, diabetes mellitus, family history of CAD, three-vessel 
CAD, renal dysfunction (estimated glomerular filtration 
rate (eGFR) <60 mL/min/1.73 m2), culprit vessel left main 
and incomplete revascularisation. The results of the multi-
variate Cox regression analysis were reported as HR and 
their respective 95% CI. Statistical analysis was performed 
using SPSS software (Version 22.0). A two-sided p value 
of <0.05 was considered statistically significant.
results
Patients
Of 1133 patients with acute first STEMI, 542 had 
multivessel CAD on CAG. Additionally, 24 patients (4%) 
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Table 1 Patient characteristics and angiographic data
Total
N=518
Incomplete 
revascularisation*
n=287
Complete 
revascularisation*
n=231 p Value
Gender (male) 76% 74% 78% 0.24
Age (years) 63±12 64±13 62±12 0.02
Obesity (BMI≥30 kg/m2) 16% 17% 15% 0.41
Diabetes 12% 14% 10% 0.15
Hypercholesterolaemia† 17% 19% 15% 0.30
Hypertension‡ 37% 40% 34% 0.17
Current smoker 44% 43% 45% 0.58
Family history of CAD 38% 38% 38% 0.90
Presenting in Killip class≥2 7% 10% 4% 0.006
Culprit vessel
 Left main 1% 1% 2% 0.50
  RCA 42% 39% 45% 0.20
  LAD 41% 46% 35% 0.02
  LCx 16% 14% 18% 0.19
Three-vessel CAD 33% 42% 22% <0.001
eGFR ≤60 mL/min/1.73 m² 13% 15% 9% 0.04
Troponin T level 4.57
(IQR 1.77–8.93)
4.91
(IQR 1.86–9.22)
4.40
(IQR 1.58–8.60)
0.28
Peak cardiac troponin T level ≥3.5 µg/L 59% 61% 56% 0.18
LV ejection fraction 47±10 46±10 47±10 0.07
LV ejection fraction ≤40% 28% 31% 25% 0.13
Blood pressure at discharge
  Systolic 116±17 115±16 118±18 0.10
  Diastolic 70±11 69±10 71±12 0.12
Medication at discharge
  Beta-blocker 93% 92% 94% 0.36
  Aspirin 96% 96% 97% 0.75
  Clopidogrel 99% 99% 99% 0.80
  ACE inhibitor/ARB 96% 96% 97% 0.55
  Statin 98% 98% 98% 0.71
*Complete revascularisation was defined as treating all present significant coronary artery stenosis ≥70% during primary PCI or before 
discharge.
†Serum total cholesterol ≥230 mg/dL and/or serum triglycerides ≥200 mg/dL or treatment with lipid-lowering drugs.
‡Defined as systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg and/or the use of antihypertensive medication.
ARB, angiotensin receptor blockers; BMI, body mass index; CAD, coronary artery disease; eGFR, glomerular filtration rate estimated 
using the Cockroft-Gault formula; LAD, left anterior descending coronary artery; LCx, left circumflex coronary artery; LV, left ventricle; PCI, 
percutaneous coronary intervention; RCA, right coronary artery; STEMI, ST-segment elevation myocardial infarction.
 A two-sided p value of <0.05 was considered statistically significant.
were excluded because of revascularisation with coro-
nary artery bypass graft surgery before discharge (n=8) or 
incomplete or uninterpretable CAG data (n=16). The clin-
ical baseline characteristics of the remaining 518 patients 
are shown in table 1. The majority of patients were male 
(76%), with a mean age of 63±12 years and in one-third 
of the patients emergent CAG showed three-vessel CAD. 
At presentation, 36 patients (7%) were in Killip class ≥2. 
Complete revascularisation was performed in 231 patients 
(45%): in 197 patients (85%) during primary PCI and 
in 34 patients (15%) during staged revascularisation 
before discharge. Differences in baseline characteristics 
between patients with incomplete and complete revascu-
larisation are presented in table 1. Patients who received 
complete revascularisation before discharge were younger, 
presented less often with Killip class ≥2, had the left ante-
rior descending coronary artery less often as culprit vessel, 
had more often two-vessel CAD and had more often 
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Table 2 Differences in baseline characteristics between patients who died within the first 30 days post-STEMI and those who 
survived
Deceased within the first 30 days 
post-STEMI
n=31
Survived the first 30 days 
post-STEMI
n=487 p Value
Gender (male) 55% 77% 0.005
Age (years) 74±12 62±12 <0.001
Obesity (BMI≥30 kg/m2) 29% 16% 0.13
Diabetes 10% 12% 0.8
Hypercholesterolaemia* 14% 17% 0.63
Hypertension† 31% 37% 0.49
Current smoker 32% 45% 0.20
Family history of CAD 11% 40% 0.003
Presenting in Killip class≥2 61% 4% <0.001
Culprit vessel
   Left main 16% 0.4% <0.001
   RCA 29% 43% 0.13
  LAD 42% 41% 0.91
  LCx 13% 16% 0.65
Three-vessel CAD 55% 32% 0.008
Incomplete revascularisation‡ 77% 54% 0.01
eGFR≤60 mL/min/1.73 m2 48% 11% <0.001
Peak cardiac troponin T level ≥3.5 µg/L 83% 58% 0.01
LV ejection fraction ≤40% 70% 27% <0.001
*Serum total cholesterol ≥230 mg/dL and/or serum triglycerides ≥200 mg/dL or treatment with lipid-lowering drugs.
†Defined as systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg and/or the use of antihypertensive medication.
‡Complete revascularisation was defined as treating all present significant coronary artery stenosis ≥70% during primary PCI or before 
discharge.
BMI, body mass index; CAD, coronary artery disease; eGFR, glomerular filtration rate estimated using the Cockroft-Gault formula; LAD, left 
anterior descending coronary artery; LCx, left circumflex coronary artery; PCI, percutaneous coronary intervention; LV, left ventricle; RCA, 
right coronary artery; STEMI, ST-segment elevation myocardial infarction.
 A two-sided p value of <0.05 was considered statistically significant.
preserved renal function as compared with patients who 
received incomplete revascularisation.
30-day mortality
In the first 30 days post-STEMI, 31 patients (6%) died 
(28 during index hospitalisation). The cause of death 
was cardiac in 27 patients (87%), terminal postanoxic 
encephalopathy in 1 patient (3%) and unknown reason 
in 3 patients (10%). The cardiac causes of death were 
cardiogenic shock (17 patients, 63%), ventricular fibril-
lation (1 patient, 4%), left-ventricular free wall rupture 
(1 patient, 4%), terminal heart failure (6 patients, 
22%) and reinfarction due to intrastent thrombosis (2 
patients, 7%). Table 2 shows the differences in base-
line characteristics between the deceased patients and 
those who survived the first 30 days post-STEMI. The 
variables (independently) associated with the end point 
30-day mortality are shown in table 3. In the multivar-
iate analysis age, Killip class ≥2 and left main coronary 
artery as the culprit vessel were independently associated 
with increased 30-day mortality post-STEMI. However, 
incomplete revascularisation was not independently asso-
ciated with increased 30-day mortality post-STEMI (OR 
1.98 (95% CI 0.62 to 6.37), p=0.25).
long-term follow-up
Long-term follow-up was complete in all patients with a 
median follow-up of 6.7 years (IQR 5.6–7.9 years). Nine-
ty-eight patients died; 67 of them (68%) died after 30 days 
post-STEMI. The Kaplan-Meier survival curves stratified 
according to complete versus incomplete revascularisa-
tion are presented in figure 1. Patients with STEMI with 
multi-vessel CAD and incomplete revascularisation showed 
higher mortality rates compared with patients who received 
complete revascularisation (24% vs 12%, p<0.001).
The cumulative mortality rates at 1, 2 and 5 years of 
follow-up were significantly higher for patients who were 
treated with incomplete revascularisation compared 
with patients who underwent complete revascularisation 
(9.8%,12.2% and 18.8% vs 4.3%, 5.2% and 6.9%, respec-
tively, p=0.02, p=0.006 and p<0.001, respectively). After 
excluding the patients who died within the first 30 days 
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Table 3 Influence of baseline characteristics on 30-day mortality post-STEMI
Univariate Multivariate
OR 95% CI p Value OR 95% CI p Value
Gender (male) 0.36 0.17 to 0.75 0.006
Age (years) 1.09 1.05 to 1.13 <0.001 1.10 1.05 to 1.15 <0.001
Diabetes 0.85 0.25 to 2.91 0.80
Hypercholesterolaemia* 0.77 0.26 to 2.26 0.63
Hypertension† 0.75 0.34 to 1.69 0.49
Current smoker 0.59 0.26 to 1.33 0.20
Family history of CAD 0.19 0.06 to 0.64 0.007
Presenting in Killip class≥2 38.42 16.32 to 90.43 <0.001 29.00 10.78 to 77.99 <0.001
Culprit vessel
  Left main 46.64 8.63 to 251.88 <0.001 48.16 4.43 to 523.47 0.001
   RCA 0.55 0.25 to 1.22 0.14
  LAD 1.05 0.50 to 2.18 0.91
  LCx 0.78 0.26 to 2.28 0.65
Three-vessel CAD 2.63 1.26 to 5.46 0.01 0.90 0.33 to 2.44 0.84
Incomplete revascularisation‡ 2.92 1.24 to 6.91 0.02 1.98 0.62 to 6.37 0.25
eGFR ≤60 mL/min/1.73 m2 7.31 2.96 to 18.02 <0.001
Peak cardiac troponin T level ≥3.5 µg/L 3.69 1.24 to 10.95 0.02
LV ejection fraction ≤40% 6.43 2.42 to 17.11 <0.001
CAD, coronary artery disease; eGFR, glomerular filtration rate estimated using the Cockroft-Gault formula; LAD, left anterior descending 
coronary artery; LCx, left circumflex coronary artery; LV, left ventricle; PCI, percutaneous coronary intervention; RCA, right coronary artery; 
STEMI, ST-segment elevation myocardial infarction.
*Serum total cholesterol ≥230 mg/dL and/or serum triglycerides ≥200 mg/dL or treatment with lipid-lowering drugs.
†Defined as systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg and/or the use of antihypertensive medication.
‡Complete revascularisation was defined as treating all present significant coronary artery stenosis ≥70% during primary PCI or before 
discharge.
 A two-sided p value of <0.05 was considered statistically significant.
Figure 1 Kaplan-Meier curves for the end point all-cause mortality in the total patient population stratified according 
to complete/incomplete revascularisation. Patients with incomplete revascularisation had a statistically significant higher 
cumulative incidence of all-cause mortality (p (log-rank)<0.001) during long-term follow-up after ST-segment elevation 
myocardial infarction in comparison with patients with complete revascularisation.
from the analysis, incomplete revascularisation was asso-
ciated with worse long-term survival compared with 
complete revascularisation (p=0.012; figure 2). However, 
multivariate Cox regression analysis showed that incom-
plete revascularisation was not independently associated 
with increased all-cause mortality (table 4). Age and left 
main coronary artery as the culprit vessel were inde-
pendently associated with the end point of all-cause 
mortality. After excluding patients presenting in cardio-
genic shock (Killip class 4) on the day of admission (n=7), 
incomplete revascularisation was not independently 
associated with increased all-cause mortality (HR 1.56 
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Figure 2 Kaplan-Meier curve for all-cause mortality in the subgroup of survivors of the first 30 days after STEMI stratified 
according to complete/incomplete revascularisation. The survivors of the first 30 days post-STEMI with incomplete 
revascularisation compared with patients with complete revascularisation had a statistically significant higher cumulative 
incidence of all-cause mortality (p (log-rank)=0.012) during long-term follow-up after STEMI. STEMI, ST-segment elevation 
myocardial infarction.
(95% CI 0.91 to 2.69), p=0.11, see online supplementary 
table 1).
dIsCussIon
This study showed that patients with first acute STEMI 
and multivessel CAD who were treated with incomplete 
revascularisation had higher mortality rates at 30-day 
and long-term follow-up compared with patients who 
underwent complete revascularisation. However, after 
correcting for relevant clinical variables, incomplete 
revascularisation was not independently associated with 
increased all-cause mortality.
Prevalence of multivessel CAd and percutaneous 
revascularisation strategies
Multivessel CAD is present in 45%–55% of patients 
presenting with acute STEMI and is associated with 1.5-fold 
higher 30-day mortality rate compared with patients with 
STEMI with single-vessel CAD.8 14–17 It has been hypoth-
esised that complete revascularisation may improve the 
outcomes of patients with STEMI with multivessel CAD. 
However, the results of various registries and randomised 
trials are conflicting.3 4 7 9 The randomised CvLPRIT trial 
demonstrated in 296 patients with STEMI with multivessel 
CAD a significant reduction of the combined end point 
consisting of all-cause mortality, recurrent myocardial 
infarction or heart failure in the complete revascularisa-
tion group compared with the IRA-only PCI group (4.7% 
and 13%; p=0.025).4 However, data of the large National 
CV Data Registry from the USA that involved 28 936 
patients with STEMI with multivessel CAD, demonstrated 
a significantly higher mortality rate in patients with 
multivessel PCI (n=3134) in comparison with IRA-only 
PCI (n=25 802) (7.9% and 5.1%, respectively; p<0.01).7 
After adjusting for potential confounders, complete 
revascularisation was not independently associated with 
increased risk of all-cause mortality.
Current guidelines recommend to consider complete 
revascularisation in selected patients with STEMI and 
multi-vessel CAD (class IIb, level of evidence B).2 In this 
study, 45% of the patients with STEMI and multivessel 
CAD underwent complete revascularisation (85% during 
primary PCI) before hospital discharge. In other regis-
tries, the rates of complete revascularisation varied 
between 11% and 30%.7 18 19 The disparities in complete 
revascularisation rates across the several studies may 
be explained by differences in patient populations 
and operator decision making. In this study, patients 
with complete revascularisation before discharge were 
younger, presented less often with Killip class ≥2, had 
the left anterior descending coronary artery less often as 
culprit vessel, had more often two-vessel CAD and had 
more often preserved renal function. This is in agree-
ment with the National CV Data Registry where patients 
with complete revascularisation were more likely to be 
younger or presenting with cardiogenic shock.7
Incomplete revascularisation and 30-day mortality
In the current study, independent associates for the 
end point of 30-day mortality in patients with first STEMI 
with multivessel CAD were higher age, Killip class ≥2 and 
left main as culprit vessel. These observations are in line 
with the SHOCK trial, which demonstrated a high mortality 
rate in patients with acute myocardial infarction compli-
cated by cardiogenic shock and lower prevalence of left 
main disease for in-hospital survivors.20 However, similar 
to other large registries, incomplete revascularisation was 
not independently associated with the end point of 30-day 
mortality in patients with first STEMI and multivessel CAD.7 
8 18 20 The EUROTRANSFER Registry (European Registry 
on STEMI Patients Transferred for PCI with Upstream 
Use of Abciximab), including 777 patients with STEMI 
and multivessel CAD, showed that multivessel PCI (n=70) 
compared with IRA-only PCI (n=707) was associated with 
a higher risk of death at 30-day follow-up (12.9% vs 5.9%, 
respectively, p=0.04).8 However, this difference in mortality 
rate was no longer statistically significant after adjustment 
for covariates (adjusted OR 2.42 (95% CI 0.96 to 6.06)). 
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Table 4 Cox regression analysis for all-cause mortality during long-term follow-up in the group of patients with STEMI who 
survived the first 30 days post-STEMI
Univariate Multivariate
HR 95% CI p Value HR 95% CI p Value
Gender (male) 0.99 0.56 to 1.73 0.96
Age (years) 1.07 1.04 to 1.09 <0.001 1.05 1.03 to 1.08 <0.001
Diabetes 2.28 1.27 to 4.12 0.006 1.82 0.99 to 3.34 0.054
Hypercholesterolaemia* 0.46 0.20 to 1.06 0.07
Hypertension† 1.20 0.74 to 1.96 0.46
Current smoker 0.91 0.56 to 1.48 0.71
Family history of CAD 0.57 0.33 to 0.97 0.04 0.75 0.43 to 1.32 0.32
Presenting in Killip class≥2 1.47 0.53 to 4.05 0.46
Culprit vessel
 Left main 9.49 2.31 to 38.94 0.002 8.40 1.89 to 37.39 0.005
 RCA 0.86 0.52 to 1.40 0.54
 LAD 1.24 0.77 to 2.00 0.39
 LCx 0.71 0.34 to 1.48 0.35
Three-vessel CAD 1.95 1.21 to 3.16 0.006 1.34 0.80 to 2.23 0.26
eGFR ≤60 mL/min/1.73 m2 2.50 1.40 to 4.44 0.002 0.93 0.48 to 1.80 0.83
Peak cardiac troponin T level ≥3.5 µg/L 1.31 0.79 to 2.17 0.30
LV ejection fraction ≤40% 1.43 0.85 to 2.41 0.18
Medication at discharge
Beta-blocker 0.75 0.30 to 1.87 0.54
Aspirin 0.50 0.18 to 1.37 0.18
Clopidogrel 20.28 0.00 to 4,6·107 0.69
ACE inhibitor/ARB 0.76 0.24 to 2.42 0.64
Statin 0.81 0.11 to 5.86 0.84
Incomplete revascularisation‡ 1.91 1.14 to 3.20 0.01 1.53 0.89 to 2.61 0.12
ARB, angiotensin receptor blockers; eGFR, glomerular filtration rate estimated using the Cockroft-Gault formula; LAD, left anterior 
descending coronary artery; LCx, left circumflex coronary artery; LV, left ventricle; PCI, percutaneous coronary intervention; RCA, right 
coronary artery; STEMI, ST-segment elevation myocardial infarction.
*Serum total cholesterol ≥230 mg/dL and/or serum triglycerides ≥200 mg/dL or treatment with lipid-lowering drugs.
†Defined as systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg and/or the use of antihypertensive medication.
‡Complete revascularisation was defined as treating all present significant coronary artery stenosis ≥70% during primary PCI or before 
discharge.
Similar findings were reported by the large National CV 
Data Registry from the USA.7
These findings contrast with the results of two recent 
randomised trials demonstrating short-term benefit of 
complete revascularisation in comparison with incom-
plete revascularisation in patients with acute STEMI with 
multivessel CAD.3 4 The PRAMI trial enrolled 465 patients 
with STEMI with multivessel CAD randomly assigned to 
multivessel PCI (n=234) or IRA-only PCI (n=231) and 
compared the groups for the occurrence of combined 
end point of cardiac death, non-fatal myocardial infarc-
tion or refractory angina.3 This study was prematurely 
terminated because of a highly statistically significant 
difference (p<0.001) in the primary outcome, favouring 
multivessel PCI. Complete revascularisation was associated 
with risk reduction within 6 months after the procedure 
in comparison with the IRA-only PCI. These findings were 
similar to those reported by the CvLPRIT trial investiga-
tors.4 In this open-labelled randomised study, the impact 
of complete revascularisation at index admission (n=150) 
on short-term outcomes was compared with IRA-only PCI 
(n=146). At 30-day follow-up, patients allocated to the 
complete revascularisation arm showed lower rates of 
all-cause mortality, recurrent myocardial infarction, heart 
failure and ischaemic driven revascularisation compared 
with patients treated with PCI of the IRA-only (HR 0.45 
(95% CI 0.19 to 1.04); p=0.055). These conflicting results 
may be explained by patient characteristics and selection 
bias. Patients included in the registries showed higher 
risk (older age, associated comorbidities and higher 
frequency of cardiogenic shock) compared with those 
included in the randomised trials.
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A large meta-analysis by Moretti et al21 demonstrated 
that the only benefit of complete revascularisation 
in patients with STEMI with multivessel CAD during 
short-term follow-up (1 year) related to less repeated 
revascularisation compared with patients with IRA-only 
revascularisation.
Incomplete revascularisation and long-term follow-up
Data on the impact of complete revascularisation in 
patients with STEMI with multivessel CAD on long-term 
outcome are limited. The PRAMI trial showed a non-sig-
nificant risk reduction of cardiac death in the multivessel 
PCI group (n=234) in comparison with the IRA-only PCI 
(n=231) during a mean follow-up of 23 months (HR 
0.34; 95% CI 0.11 to 1.08; p=0.07).3 Similar findings were 
reported by the DANAMI-3-PRIMULTI which showed no 
significant difference in all-cause mortality in 627 patients 
randomly allocated to no further invasive treatment or to 
complete fractional flow reserve (FFR)-guided revascular-
isation before discharge (HR 1.40; 95% CI 0.63 to 3.00, 
p=0.43).5 Furthermore, in a study including 214 patients 
with STEMI with multivessel CAD, there were no differ-
ences in mortality rates at 2.5 years follow-up between 
IRA-only PCI, staged revascularisation and complete 
revascularisation during primary PCI (15.5%, 6.2% and 
9.2% respectively, p=0.17).10 In addition, Hannan et al9 
showed comparable 12-, 24- and 42-month mortality rates 
in patients with IRA-only PCI (n=503) and multivessel 
PCI (n=503). After exclusion of patients with haemody-
namic instability, left-ventricular ejection fraction ≤20% 
and malignant-ventricular arrhythmia, there were no 
differences in mortality rates between the two groups.
The results of this study are in line with the above-men-
tioned studies. Patients with STEMI with multivessel 
CAD who received incomplete revascularisation showed 
an increased long-term mortality rate compared with 
patients who underwent complete revascularisation (24% 
vs 12%, p<0.001). However, multivariate analysis showed 
that incomplete revascularisation was not independently 
associated with increased all-cause mortality.
The results of the COMPLETE trial ( ClinicalTrials. gov 
Identifier NCT01740479), including more than 3900 
patients who will be randomised and followed-up during 
a mean of 4 years, may shed light on this clinically rele-
vant question.
limitations
This study has some limitations that need to be addressed. 
First, this is a retrospective study. Second, patients with 
cardiogenic shock were not all completely revascularised. 
Following current guidelines, in this subgroup of patients, 
if there were truly critical (≥90%) stenoses or highly 
unstable lesions and if there was persistent ischaemia after 
PCI of the culprit lesion, complete revascularisation was 
performed.2 However, non-culprit lesions without critical 
stenoses were not routinely stented.2 Additional analysis 
after excluding patients in cardiogenic shock at the time 
of admission demonstrated similar results: incomplete 
revascularisation was not independently associated with 
increased all-cause mortality during long-term follow-up. 
Third, the characteristics of the stents used during PCI in 
the current study were not taken into account. Further-
more, the presence of chronic total occlusions of the 
coronary arteries was not recorded. In addition, to avoid 
misclassification of the cause of death, this study inves-
tigated only all-cause mortality.22 Moreover, although 
patients are advised to follow a cardiac rehabilitation 
programme after hospital discharge, data on adherence 
to these programmes were not available, and this could 
have influenced the survival rate. 
ConClusIon
Incomplete revascularisation in patients with acute first 
STEMI and multivessel CAD was not independently asso-
ciated with increased short-term and long-term all-cause 
mortality.
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